Several epidemiological studies suggest that moderate consumption of alcohol, particularly red wine, lowers mortality rates from coronary heart disease (CHD) [ 1 Rimm E.B. Giovannucci E.L. Willet W.C. Colditz G.A. Aschrio A. Rosner B. et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet. 1991; 338: 464-468 Abstract PubMed Scopus (1043) Google Scholar , 2 Jackson R. Scragg R. Beaglehole R. Alcohol consumption and risk of coronary heart disease. Br. Med. J. 1991; 303: 211-216 Crossref PubMed Scopus (195) Google Scholar , 3 Rimm E.B. Klatsky A. Grobbee D. Stampfer M.J. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. Br. Med. J. 1996; 312: 731-736 Crossref PubMed Scopus (862) Google Scholar , 4 Renaud S. De Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1993; 339: 1523-1526 Abstract Scopus (3121) Google Scholar , 5 Booyse F.M. Parks D.A. Moderate wine and alcohol consumption: beneficial effects on cardiovascular disease. Thromb. Haemost. 2001; 86: 517-528 PubMed Google Scholar ]. Since red wines are rich in flavonoids and other polyphenolic constituents, various red wine components have been studied for anti-atherogenic effects [ [6] Soleas G.J. Diamandis E.P. Goldberg D.M. Wine as biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal. 1997; 11: 287-313 Crossref PubMed Scopus (607) Google Scholar ]. Resveratrol (3,4′,5-trihydoxy-trans-stilbene), a polyphenolic compound present in red wine, has been thought to be the active ingredient responsible for cardiovascular benefits associated with wine consumption as it was found to be the active ingredient of the oriental folk medicine kojo-kon, used for a multitude of therapeutic purposes, including heart diseases [ 7 Nonomura S. Kanagawa H. Makimoto A. Chemical constituents of polygonaceous plants: I. Studies on the components of Ko-jo-kon. Yakugaku Zasshi. 1963; 83: 988 PubMed Google Scholar , 8 Siemann E.H. Creasy L.L. Concentration of the phytoalexin resveratrol in wine. Am. J. Enol. Vitic. 1992; 43: 49-52 Google Scholar ], and shown to protect human LDL against oxidation [ [9] Frankel E.N. Waterhouse A.L. Kinsella J.E. Inhibitions of human LDL oxidation by resveratrol. Lancet. 1993; 341: 1103-1104 Abstract PubMed Scopus (877) Google Scholar ] and inhibit platelet aggregation [ 10 Bertelli A.A.E. Giovannini L. Giannessi D. Migliori M. Bernini W. Fregoni M. et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React. 1995; 17: 1-3 PubMed Google Scholar , 11 Pace-Asciak C.R. Hahn S. Diamandis E.P. Soleas G. Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta. 1995; 235: 207-219 Crossref PubMed Scopus (864) Google Scholar ]. Resveratrol was also shown to inhibit synthesis of proatherogenic eicosanoids [ [11] Pace-Asciak C.R. Hahn S. Diamandis E.P. Soleas G. Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta. 1995; 235: 207-219 Crossref PubMed Scopus (864) Google Scholar ], endothelial cell activation [ [12] Bertelli A.A. Baccalini R. Battaglia E. Falchi M. Ferrero M.E. Resveratrol inhibits TNF alpha-induced endothelial cell activation. Therapie. 2001; 56: 613-616 PubMed Google Scholar ], cell proliferation [ [13] Igura K. Ohta T. Kuroda Y. Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 2001; 171: 11-16 Abstract Full Text Full Text PDF PubMed Scopus (203) Google Scholar ], and affect various other cellular responses [ [14] Frémont L. Biological effects of resveratrol. Life Sci. 2000; 66: 663-673 Crossref PubMed Scopus (1399) Google Scholar ].